year [1] . STS can occur in any anatomical location [2] , and surgical excision with or without adjuvant radiotherapy is the usual treatment for localised disease [3] . However, there is a significant risk of local recurrence and metastasis following primary treatment. Ten-year local recurrence rates are between 10 and 20%, and ten-year survival is 50 to 60% [4, 5] Within this, there can be significant variability by tumour type, size and location [6, 7] . Prognostic factors for tumour relapse are complex; the risk of metastasis is associated with tumour grade, size and depth, while local recurrence risk is associated with grade and excision margin [5] .
Given the risk of recurrence or metastasis following primary treatment, STS patients require long-term follow-up, which may continue for up to ten years. However, there remains controversy as to the optimum patient follow-up regime, and follow-up may produce either reassurance or anxiety for patients [8, 9] , particularly as 40% or more of patients will never develop recurrent disease [1, 10] .
Routine follow-up includes clinical examination and regular chest x-rays, but the value of more sophisticated follow-up investigations remains uncertain [1] . US studies demonstrate significant heterogeneity in clinical practice [11, 12] . The American National Comprehensive Cancer Network and American College of Radiology have produced consensus-based guidelines for sarcoma follow-up [13] , stratified by grade and tumour site. A survey of UK practice showed differences in the length of follow-up, frequency of consultations and the investigations undertaken at follow-up visits [14] . The National Comprehensive Cancer Network in the UK has issued post-treatment guidelines for the clinical management of STS but these are consensus rather than evidence-based [15] . Finally, the European Society for Medical Oncology (ESMO) has issued its own follow-up guidelines, recommending tailored patient follow-up regimes based on risk assessments of tumour grade, size and site [16] . In addition to clinical uncertainty about STS follow-up, there is no published work assessing the acceptability of different potential posttreatment regimes from the patient perspective.
This study aimed to assess the patient acceptability of different follow-up strategies following curative STS surgery and to investigate the hypothetical levels of recurrence risk at which different follow-up regimes were acceptable.
PATIENTS AND METHODS
This study used a cross-sectional survey incorporating a best-worst scaling (BWS) discrete choice experiment (DCE) to elicit information regarding patient preferences for different aspects of the STS follow-up regime. Participants were also asked to choose between low, moderate and intensive follow-up schedules at a range of hypothetical recurrence risks from 0% to 100%.
Patient recruitment and data collection
The Royal Orthopaedic Hospital (ROH) maintains a database of patients treated for soft tissue sarcoma, which was searched by a research nurse to identify eligible participants aged 18 and over, with a diagnosis of any soft tissue tumour (excluding retroperitoneal or periabdominal sarcomas as these patients are not followed up at ROH) who had undergone curative treatment. Patients were not eligible for the study if they were aged under 18 at the time of primary treatment, were diagnosed fewer than 6 months or more than 10 years previously, or had a serious or unstable medical or psychological condition that would compromise study participation.
All eligible patients were posted a study information pack seven days before their next follow-up clinic visit. On arrival at the clinic, the research nurse took informed consent from those who wished to participate in the study, and administered the survey and DCE. Sociodemographic information (age, gender, employment status, education level, distance between patients' home and ROH) was collected, and anonymised clinical information was extracted from the hospital database for each participant. This included data relating to primary treatment (age, date of diagnosis and treatment, STS histology, tumour size, grade, site), and any information relating to disease recurrence.
Discrete choice experiment and best-worst scaling
Discrete choice experiments (DCE) elicit preferences for goods or services based on individual intentions in hypothetical situations [17] . The DCE method has several variants; this study used the best-worst scaling method [18, 19] , which identifies patient preferences for healthcare
service provision by examining trade-offs that individuals are prepared to make between different aspects of healthcare. BWS involves identification of key characteristics (attributes), each of which has two or more levels, in order to develop a series of scenarios incorporating various combinations of attribute levels to describe different aspects of healthcare service provision [20] . Attributes were derived from published literature [11, 12, 14] , and clinical guidelines [15, [21] [22] [23] . [24] . For each scenario, participants were asked to choose the aspect that they perceived as the best and worst option ( Figure 1 ). 
Acceptability of follow-up at different risks of recurrence

Justification of sample size
The sample size was based on pragmatic rather than statistical criteria and was maximised within the resources available. It was anticipated that 300 patients would be eligible to participate during the data collection period (May to December 2012). Achieving a 60% response rate would thus give a sample size of 180 patients.
RESULTS
Response rates
286 patients were eligible to participate over the data collection period. 133 patients consented to participate, representing a 47% response rate. One participant withdrew after consenting, thus data were collected for 132 patients in total.
Participant clinical and sociodemographic characteristics
73 participants were male (55%) and 59 were female (45%), ( Mean tumour size (diameter) at diagnosis was 9.2cm.
Participant views about follow-up
Participants were asked for their general views about STS follow-up and its perceived importance. All participants felt that attending follow-up visits was important, and the vast majority (n=130; 99%) understood why follow-up visits were necessary. Most respondents felt it important to be included in decision-making about their follow-up regime (n=114; 86%). The most important broad aspect of follow-up visits for most participants was the nature of clinical investigations undertaken (n=96; 73%). The type of healthcare provider conducting follow-up was deemed the least important factor (n=7; 5%). Table 2 shows the frequency with which specific attributes and levels were selected as best or Although studies comparing the acceptability of GP vs. hospital clinic follow-up have been undertaken for other tumour types (such as breast cancer) and shown that GP follow-up was perceived favourably by patients [25] , participants in this study expressed strong preferences for follow-up to remain in secondary care, as the greatest gain in utility between levels evident within a single attribute was the difference between GP follow-up and follow-up undertaken by a specialist hospital doctor. This may be because patients with STS often experience diagnostic delays within general practice [26] and as a consequence, may have less confidence in their GP facilitating long-term follow-up after completion of treatment. Furthermore, the rarity of soft tissue sarcoma and generally poor prognosis after treatment may be a factor in the observed strong patient preference for specialist follow-up and ongoing monitoring.
Discrete choice experiment best-worst scaling
Acceptability of follow-up schedule by hypothetical risk of disease recurrence
M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT
intensive and the lack of consensus about the optimal follow-up strategy has led to significant variation in clinical practice within and between countries. Follow-up is a question of balancing multiple objectives, including maximising patient survival, quality of life, psychological outcomes and physical function [27] . There is clearly some scope for tailored follow-up regimes developed on a case-by-case basis. This study has shown that whilst patient follow-up preferences were generally homogeneous, these preferences changed once the issue of recurrence risk was considered. The thresholds at which patient preferences for follow-up changed between the potential low, moderate and intensive regimes were extremely low: hypothetical local recurrence risks under 1% were associated with a preference for low intensity follow-up regimes, but incremental increases in recurrence risk prompted preferences for higher intensity strategies.
Indeed, once the hypothetical risk of recurrence rose above 5%, the majority of patients stated that an intensive follow-up regime would be most acceptable.
Whilst it is encouraging that patient preferences for sarcoma follow-up do not appear to differ significantly from the follow-up regime typically offered by most treatment and surveillance centres, it is likely that the broad agreement between patient preference and the current routine 
M A N U S C R I P T A C C E P T E D
Number of participants
Risk of recurrence (%)
Low Moderate Intensive
